Timothy T. Goodnow net worth and biography

Timothy Goodnow Biography and Net Worth

CEO of Senseonics Holdings, Inc. Common Stock

Tim Goodnow is the President and Chief Executive Officer at Senseonics, Inc.

Tim joined the Senseonics Board of Directors in December 2010 and in March 2011 was named President & CEO. Tim has been instrumental in commercializing the first 90-day Eversense CGM System in Europe and the 180-day product - Eversense XL - which is now distributed in more than 15 countries. He also successfully launched Eversense in the U.S. only 40 days after FDA approval. Tim continues to drive innovation, product development and new technology for future CGM systems.

Prior to Senseonics, Tim was Vice President of Technical Operations at Abbott Diabetes Care. He also held executive positions at TheraSense, Verax Biomedical, Dade Behring and Baxter Healthcare.

Tim earned his PhD and Bachelor of Science degree in Chemistry at the University of Miami.

What is Timothy T. Goodnow's net worth?: The estimated net worth of Timothy T. Goodnow is at least $3.20 million as of December 10th, 2024. Goodnow owns 565,517 shares of Senseonics Holdings, Inc. Common Stock stock worth more than $3,195,737 as of March 13th. This net worth approximation does not reflect any other investments that Goodnow may own. Learn More about Timothy T. Goodnow's net worth.
How do I contact Timothy T. Goodnow?: The corporate mailing address for Goodnow and other Senseonics Holdings, Inc. Common Stock executives is 20451 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876. Senseonics Holdings, Inc. Common Stock can also be reached via phone at (301) 515-7260 and via email at [email protected]. Learn More on Timothy T. Goodnow's contact information.
Has Timothy T. Goodnow been buying or selling shares of Senseonics Holdings, Inc. Common Stock?: Timothy T. Goodnow has not been actively trading shares of Senseonics Holdings, Inc. Common Stock in the last ninety days. Most recently, on Tuesday, December 10th, Timothy T. Goodnow bought 15,750 shares of Senseonics Holdings, Inc. Common Stock stock. The stock was acquired at an average cost of $6.20 per share, with a total value of $97,650.00. Following the completion of the transaction, the chief executive officer now directly owns 565,517 shares of the company's stock, valued at $3,506,205.40. Learn More on Timothy T. Goodnow's trading history.
Who are Senseonics Holdings, Inc. Common Stock's active insiders?: Senseonics Holdings, Inc. Common Stock's insider roster includes Timothy Goodnow (CEO), Sharon Larkin (Director), Douglas Roeder (Director), and Frederick Sullivan (CFO). Learn More on Senseonics Holdings, Inc. Common Stock's active insiders.
Are insiders buying or selling shares of Senseonics Holdings, Inc. Common Stock?: In the last twelve months, Senseonics Holdings, Inc. Common Stock insiders bought shares 3 times. They purchased a total of 30,415 shares worth more than $184,790.20. The most recent insider tranaction occured on November, 10th when Director Edelman Steven bought 10,000 shares worth more than $65,500.00. Insiders at Senseonics Holdings, Inc. Common Stock own 3.6% of the company. Learn More about insider trades at Senseonics Holdings, Inc. Common Stock.
Information on this page was last updated on 11/10/2025.

Timothy T. Goodnow Insider Trading History at Senseonics Holdings, Inc. Common Stock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/10/2024	Buy	15,750	$6.20	$97,650.00	565,517
2/11/2022	Sell	23,219	$49.20	$1,142,374.80
6/10/2021	Sell	19,035	$72.00	$1,370,520.00	260,579
9/9/2019	Buy	4,425	$22.00	$97,350.00

Timothy T. Goodnow Buying and Selling Activity at Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc. Common Stock Company Overview

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Today's Range

Now: $5.64

$5.58

$5.93

50 Day Range

MA: N/A

2 Week Range

Now: $5.64

$5.25

$15.74

Volume

455,894 shs

Average Volume

504,173 shs

Market Capitalization

$235.58 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.9